Safety and Bioactivity of AXT107 in Subjects With Neovascular Age-Related Macular Degeneration
Clinical trial NCT04746963 · TERMINATED
Trial details
- NCT number
- NCT04746963
- Sponsor
- AsclepiX Therapeutics, Inc.
- Status
- TERMINATED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-02-01
- Primary completion
- 2022-10-01
- Enrollment
- 3
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.